Search This Blog

Monday, September 25, 2023

Lufthansa Says Green Fuel Would Eat Up Half German Electricity

 

Germany’s biggest airline would consume half of the country’s entire electricity production to switch its fleet to green fuels like e-kerosene, according to Deutsche Lufthansa AG, underscoring the challenge in reducing emissions from air transport.

While synthetic fuels manufactured using renewable energy provided the best future path to decarbonize aviation, there is unlikely to be sufficient green electricity in Germany to generate them, Lufthansa Chief Executive Officer Carsten Spohr on Monday

https://www.bloomberg.com/news/articles/2023-09-25/lufthansa-says-green-fuel-would-eat-up-half-german-electricity

BridgeBio: $250 Million Private Placement Equity with Qatari

  $250 million financing led by Qatar Investment Authority (QIA) with significant participation from four of the largest investment management firms in the US

- BridgeBio anticipates this raise, coupled with several less dilutive financings available to the Company, fully capitalizes the Company to profitability

https://finance.yahoo.com/news/bridgebio-pharma-announces-250-million-113000243.html

SEC collects Wall Street's private messages as WhatsApp probe escalates -sources

  The U.S. securities regulator has collected thousands of staff messages from more than a dozen major investment companies, escalating its probe into Wall Street's use of private messaging apps, said four people with direct knowledge of the matter.

Previously, the Securities and Exchange Commission (SEC) had asked the companies to internally review the messages in its investigation of Wall Street's use of WhatsApp, Signal and other unapproved messaging apps to discuss work.

The two-year crackdown into potential breaches of record-keeping rules initially targeted broker dealers, netting regulators over $2 billion in fines.

While Reuters and other media have reported that the SEC's "off-channel" communication probe has expanded to investment advisers, its move to review thousands of their staff messages has not previously been reported. It marks an escalation of the investigation and raises the stakes for the companies and the executives concerned by exposing their conduct to SEC scrutiny.

https://finance.yahoo.com/news/exclusive-sec-collects-wall-streets-100358963.html

Sunday, September 24, 2023

Lego abandons effort to make oil-free bricks, Financial Times reports

Danish Toymaker Lego has abandoned its effort to ditch oil-based plastics from its bricks after finding that its new material led to higher carbon emissions, the Financial Times reported on Sunday.

Lego found that bricks made from recycled polyethylene terephthalate (RPET), would lead to higher carbon emissions.

"We tested hundreds and hundreds of materials. It's just not been possible to find a material like that," Lego Chief Executive Niels Christiansen told the Financial times.

Reuters was not able to independently verify the details of the FT report. Lego did not immediately respond to Reuters' request for comment.

Lego had earlier pledged to replace oil-based plastic bricks with ones made from sustainable materials by the end of the decade.

The company had kicked off efforts in 2020 to replace its plastic bricks by sustainable materials. The difficulty was to find a material that would be environment friendly but give the same color, shine and sound of an oil-based plastic bricks.\

https://finance.yahoo.com/news/lego-abandons-effort-oil-free-213537162.html

Novartis: progression-free survival in first line advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

 

  • Phase III NETTER-2 trial met primary endpoint of improvement in progression-free survival (PFS) and key secondary endpoint of objective response rate (ORR) in patients with Grade 2 and 3 advanced gastroenteropancreatic neuroendocrine tumors (GEP-NETs) who received first line treatment with Lutathera® in combination with long-acting octreotide, versus high-dose long-acting octreotide alone1,2

  • Lutathera is the first radioligand therapy (RLT) to demonstrate clinically meaningful benefit in a first line setting1

  • Findings to be presented at an upcoming medical meeting and discussed with regulatory authorities, with submissions to follow

  • Novartis is investigating a broad portfolio of RLTs, exploring their treatment potential in a range of advanced cancers beyond prostate and GEP-NET, including lung, breast, pancreatic and colon. The company also continues to support the increasing demand for RLTs with expansions at existing manufacturing sites in the U.S. and Europe and a new state-of-the-art facility in Indianapolis, U.S., which is awaiting FDA approval

CDC Refuses To Release Updated Information On Post-COVID Vaccination Heart Inflammation

by Zachary Stieber via The Epoch Times,

The U.S. Centers for Disease Control and Prevention (CDC) is refusing to release updated information on reported cases of myocarditis and pericarditis following COVID-19 vaccination.

COVID-19 vaccines can cause the inflammatory conditions, the CDC has confirmed previously.

The agency has regularly conveyed the number of post-vaccination myocarditis and pericarditis cases to the Vaccine Adverse Event Reporting System (VAERS), which it helps manage, as it has consulted with its advisers on updates to the vaccines.

But during a meeting on Sept. 12, the CDC did not mention VAERS data.

Asked for the information, a CDC spokesman pointed to a CDC study that covers data only through Oct. 23, 2022.

That study identified nine reports of myocarditis or pericarditis following vaccination with one of the bivalent COVID-19 vaccines, which were introduced in September 2022. Seven of the reports were verified by medical review.

Asked for more current data, the spokesman acknowledged the agency has it but is not making it public.

"When appropriate, the updated safety data will be published," the spokesman told The Epoch Times in an email.

He did not answer when asked why the meeting was not an appropriate time.

"The CDC has acknowledged that heart inflammation is a complication of mRNA COVID-19 shots and, yet, the only published data released by CDC officials about that complication is a seven week study that ended on Oct. 23, 2022. Where is more specific myocarditis/pericarditis data related to bivalent COVID shots for the past 10 months?" Barbara Loe Fisher, co-founder and president of the National Vaccine Information Center, told The Epoch Times via email.

The mRNA shots are made by Pfizer and Moderna. Novavax's updated shot, which uses different technology, has not yet been authorized by the U.S. Food and Drug Administration (FDA).

"I am tired of the CDC and FDA deciding what information the public needs and doesn’t need. This is precisely the information that parents need to have especially when there are still schools and activities mandating these shots. This is evil playing out right before our eyes," Kim Witczak, a drug safety advocate who runs the nonprofit Woodymatters, told The Epoch Times in an email.

She added, "The CDC’s response of 'when appropriate, the updated safety data will be published' is unacceptable and they wonder why there is vaccine hesitancy and lack of trust in public health officials."

Presentation

During the recent meeting, CDC officials and their partners presented data on the bivalent shots to their advisory panel, the Advisory Committee on Immunization Practices. The advisers were considering which groups should be recommended to get one of the new COVID-19 vaccines, which were cleared by regulators with scant clinical trial data.

Dr. Nicola Klein, a Kaiser Permanente doctor who works closely with the CDC, gave a presentation (pdf) on COVID-19 vaccine safety. She presented data from the Vaccine Safety Datalink, a monitoring system that covers a much smaller population than VAERS.

Dr. Klein said that two cases of myocarditis after bivalent vaccination were detected in the Vaccine Safety Datalink (VSD) through March 11. It's not clear why more current data were not presented. Dr. Klein did not respond to a request for comment. The cases did not trigger a safety signal among adults, Dr. Klein said.

The presented data were widely cited by doctors quoted in news outlets, including Dr. Andrew Pavia, who told a briefing that there did not appear to be a "detectable risk" of the bivalent shots causing myocarditis.

"What I was conveying is that in the era of the bivalent vaccine, the number of cases has fallen to where it no longer is giving a signal that is detectable," Dr. Pavia, chief of the University of Utah's Division of Pediatric Infectious Diseases, told The Epoch Times in an email. In response to how he could say that with the missing VAERS data, he said "the strongest data are from the controlled studies like the VSD where you have built in controls."

Through Sept. 8, 98 cases of myocarditis, pericarditis, or myopericarditis were reported to VAERS following bivalent vaccination, according to a search of the system by The Epoch Times.

While anybody can lodge a report with VAERS, research has shown most reports are entered by health care providers. People who submit false information can face prosecution.

Five reports were for people aged 6 to 17 years while another 13 were for people aged 18 to 29.

When presenting to the panel, CDC official Megan Wallace said, "There are limited data to inform the myocarditis risk following an updated mRNA dose." She did not mention the cases reported to VAERS but alleged the benefits of the vaccines outweigh the risks, even for young, healthy males. The Vaccine Safety Datalink, she acknowledged, did have a "relatively lower sample size" of recipients.

Panel members were taken by the data. Dr. Oliver Brooks said "Feel good about the fact that in the bivalent we saw no signal from myocarditis," he said after the presentation. "Very important." Dr. Brooks, chief medical officer at Watts Healthcare Corporation, did not respond to an inquiry.

Dr. Pablo Sanchez, the only member to recommend against a widespread recommendation, said the risk of myocarditis was a reason.

"I think we really need to level with our patients and say what is known and unknown, rather than make a complete recommendation," he said, "especially for some groups that there are limited data."

The labels for the new vaccines say they can cause myocarditis.

"Postmarketing data with authorized or approved mRNA COVID-19 vaccines demonstrate increased risks of myocarditis and pericarditis, particularly within the first week following vaccination," the labels state. While some people have recovered, others have not. The labels also say, "Information is not yet available about potential long-term sequelae."

https://www.zerohedge.com/covid-19/cdc-refuses-release-updated-information-post-covid-vaccination-heart-inflammation

Foundry Partners Acquires Stake in InMode

 In September 2023, investment management firm Foundry Partners LLC disclosed its acquisition of a new stake in shares of InMode Ltd. (NASDAQ: INMD) during the second quarter. According to the company’s recent 13F filing with the Securities and Exchange Commission (SEC), Foundry Partners purchased 90,720 shares of InMode’s healthcare stock, amounting to approximately $3,388,000 in value. This purchase accounted for roughly 0.11% ownership of InMode at the end of the quarter.

InMode, a leading medical technology company, recently released its quarterly earnings data on July 27th. The healthcare firm reported earnings per share (EPS) of $0.65 for the quarter, meeting analysts’ consensus estimates. Additionally, InMode generated revenue of $136.08 million during this period, slightly surpassing analyst projections of $135.80 million. Notably, InMode boasted an impressive net margin of 36.77% and a return on equity of 35.03%. Analysts predict that InMode Ltd.’s fiscal year will result in an EPS of 2.45.

Based in the United States but operating internationally as well, InMode specializes in designing, developing, manufacturing, and marketing minimally invasive aesthetic medical products utilizing their proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies. The company’s product line encompasses various procedures such as liposuction with simultaneous skin tightening, body and face contouring treatments, ablative skin rejuvenation treatments, and applications within women’s health conditions and procedures.

By leveraging their innovative technologies and extensive product range, InMode seeks to address the rising demand for minimally invasive alternatives within the aesthetic medical field worldwide.

https://beststocks.com/investment-management-firm-foundry-partners-acquir/